Fate Therapeutics, Inc. FATE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +112.24%
- 1 year
- +61.24%
- Open
- 2.13
- Prev close
- 2.17
- Mkt cap
- 249.23M
- Vol
- 1.06M
- Avg vol
- 1.58M
- EPS
- -1.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.01
- High
- 2.16
- Forward P/E
- -0.99
- Beta
- 1.88
- Short ratio
- 3.10
- Inst. own
- 102.25%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.93
- 1y target
- 6.31
5D chart
Signals (57)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 27, 4:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 26, 4:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 23, 4:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:45 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 2:20 PM | 1 week ago |
| RSI: Overbought | Oct 23, 1:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:20 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 1:20 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 12:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 12:25 PM | 1 week ago |
News
-
5 days ago benzinga.com
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
-
6 days ago benzinga.com
Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
6 days ago globenewswire.com
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
-
1 month ago benzinga.com
Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive…
-
1 month ago benzinga.com
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
1 month ago benzinga.com
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
2 months ago benzinga.com
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
-
2 months ago benzinga.com
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated…
-
2 months ago benzinga.com
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of…
3 months ago benzinga.com
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales guidance. Other stocks also down in pre-market.
-
3 months ago benzinga.com
CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
3 months ago benzinga.com
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.
-
5 months ago benzinga.com
Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
5 months ago benzinga.com
Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
5 months ago benzinga.com
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of…
-
5 months ago benzinga.com
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
5 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
6 months ago benzinga.com
Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
6 months ago benzinga.com
Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15
Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to…
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7
HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.
-
6 months ago benzinga.com
Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
6 months ago benzinga.com
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
-
2 years ago benzinga.com
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
-
2 years ago benzinga.com
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 369 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 225 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 283 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 210 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 201 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 128 companies set new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For August 8, 2023
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 103 companies set new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
-
3 years ago benzinga.com
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
-
3 years ago benzinga.com
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 298 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 241 companies hit new 52-week lows.